Breast cancer stromal elastosis is associated with mammography screening detection, low Ki67 expression and favourable prognosis in a population-based study

[1]  L. Vatten,et al.  Modern mammography screening and breast cancer mortality: population study , 2014, BMJ : British Medical Journal.

[2]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[3]  S. Duffy,et al.  Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer , 2013, Breast Cancer Research.

[4]  S. Feig.  Pitfalls in accurate estimation of overdiagnosis: implications for screening policy and compliance , 2013, Breast Cancer Research.

[5]  B. Møller,et al.  Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program , 2013, Cancer.

[6]  P. Skaane,et al.  Overdiagnosis among women attending a population-based mammography screening program , 2013, International journal of cancer.

[7]  G. Mills,et al.  Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer , 2013, Breast Cancer Research.

[8]  A. Glas,et al.  Impact of mammographic screening on the detection of good and poor prognosis breast cancers , 2011, Breast Cancer Research and Treatment.

[9]  S. Mook,et al.  Independent prognostic value of screen detection in invasive breast cancer. , 2011, Journal of the National Cancer Institute.

[10]  Valerie M. Weaver,et al.  The extracellular matrix at a glance , 2010, Journal of Cell Science.

[11]  Marvin Zelen,et al.  Effect of screening mammography on breast-cancer mortality in Norway. , 2010, The New England journal of medicine.

[12]  H. Nelson,et al.  Screening for Breast Cancer: An Update for the U.S. Preventive Services Task Force , 2009, Annals of Internal Medicine.

[13]  S. Duffy,et al.  Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival , 2009, British Journal of Cancer.

[14]  Peter C Gøtzsche,et al.  Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends , 2009, BMJ : British Medical Journal.

[15]  Valerie M. Weaver,et al.  A tense situation: forcing tumour progression , 2009, Nature Reviews Cancer.

[16]  H. Welch,et al.  The natural history of invasive breast cancers detected by screening mammography. , 2008, Archives of internal medicine.

[17]  V. Kataja,et al.  Molecular Subtypes of Breast Cancers Detected in Mammography Screening and Outside of Screening , 2008, Clinical Cancer Research.

[18]  E. van Marck,et al.  Gene Expression Profiles Associated with the Presence of a Fibrotic Focus and the Growth Pattern in Lymph Node–Negative Breast Cancer , 2008, Clinical Cancer Research.

[19]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.

[20]  T. Sørlie,et al.  Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome , 2008, The Journal of pathology.

[21]  S. Hofvind,et al.  Incidence and tumor characteristics of breast cancer diagnosed before and after implementation of a population-based screening-program , 2008, Acta oncologica.

[22]  R. Mecham,et al.  New insights into elastic fiber assembly. , 2007, Birth defects research. Part C, Embryo today : reviews.

[23]  M. Kerin,et al.  Radial scars/complex sclerosing lesions and malignancy in a screening programme: incidence and histological features revisited , 2007, Histopathology.

[24]  Ian O Ellis,et al.  Is mammographic spiculation an independent, good prognostic factor in screening-detected invasive breast cancer? , 2006, AJR. American journal of roentgenology.

[25]  B. Yankaskas,et al.  Association of stellate mammographic pattern with survival in small invasive breast tumors. , 2006, AJR. American journal of roentgenology.

[26]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[27]  A. Weiss,et al.  Cellular interactions with elastin. , 2005, Pathologie-biologie.

[28]  W. Foulkes,et al.  A Basal Epithelial Phenotype Is More Frequent in Interval Breast Cancers Compared with Screen Detected Tumors , 2005, Cancer Epidemiology Biomarkers & Prevention.

[29]  V. Bécette,et al.  Stellate images: anatomic and radiologic correlations. , 2005, European journal of radiology.

[30]  V. Kataja,et al.  Risk for distant recurrence of breast cancer detected by mammography screening or other methods. , 2004, JAMA.

[31]  L. Duca,et al.  Elastin as a matrikine. , 2004, Critical reviews in oncology/hematology.

[32]  A. Ellis.  Breast , 2002, BMJ : British Medical Journal.

[33]  J. Tímár,et al.  Role of elastin-matrix interactions in tumor progression. , 2002, Seminars in cancer biology.

[34]  A. Tőkés,et al.  Extracellular matrix components in breast carcinomas. , 2002, Seminars in cancer biology.

[35]  R. Timpl,et al.  Angiogenesis inhibitor endostatin is a distinct component of elastic fibers in vessel walls , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  S. Hirohashi,et al.  Fibrotic Focus in Invasive Ductal Carcinoma: An Indicator of High Tumor Aggressiveness , 1996, Japanese journal of cancer research : Gann.

[37]  R. Gray,et al.  Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: a 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  C. Redmond,et al.  Pathologic findings from the national surgical adjuvant breast project protocol B‐06 10‐year pathologic and clinical prognostic discriminants , 1993, Cancer.

[39]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[40]  B. V. Pedersen,et al.  Elastosis in relation to prognosis in primary breast carcinoma. , 1985, Cancer research.

[41]  T. Moriizumi,et al.  AN ULTRASTRUCTURAL STUDY ON PERIDUCTAL ELASTOSIS IN HUMAN BREAST TUMORS , 1983, Acta pathologica japonica.

[42]  I. Cree,et al.  Prognostic value of measurement of elastosis in breast carcinoma. , 1981, Journal of clinical pathology.

[43]  J. Masters,et al.  Elastosis and response to endocrine therapy in human breast cancer. , 1979, British Journal of Cancer.

[44]  J. Masters,et al.  Elastosis and oestrogen receptors in human breast cancer. , 1976, British Journal of Cancer.

[45]  Douglas Jg,et al.  The origins of elastica in breast carcinoma. , 1974 .

[46]  Douglas Jg,et al.  The prognostic significance of elastosis in breast carcinoma. , 1972 .

[47]  B. Son,et al.  Correlation between mammographic and sonographic findings and prognostic factors in patients with node-negative invasive breast cancer. , 2011, The British journal of radiology.

[48]  S. Partanen,et al.  Scar and non-scar ductal cancer of the female breast , 2004, Virchows Archiv A.

[49]  W. Bogomoletz.  Elastosis in breast cancer. , 1986, Pathology annual.

[50]  J. Douglas,et al.  The origins of elastica in breast carcinoma. , 1974, Journal of the Royal College of Surgeons of Edinburgh.

[51]  J. G. Douglas,et al.  The prognostic significance of elastosis in breast carcinoma. , 1972, Journal of the Royal College of Surgeons of Edinburgh.